Immunogenicity and Safety of Recombinant Hepatitis B Vaccine(Engerix B).
- Author:
Kyung Ja LEE
1
;
Min Kee CHO
;
Woong Ki CHANG
;
Hae Sun YOON
;
Jae Kook CHA
;
Jeong Eun CHOI
;
Chong Young PARK
;
Sang Aun JOO
;
Hee Jung KANG
Author Information
1. Department of Pediatrics, College of Medicine, Hallym University, Kangwondo, Korea.
- Publication Type:Original Article
- Keywords:
Hepatitis B vaccine;
Recombinant;
Immunogenecity;
Safety
- MeSH:
Adult;
Appointments and Schedules;
Child;
Enzyme-Linked Immunosorbent Assay;
Hepatitis B Vaccines;
Hepatitis B*;
Hepatitis*;
Humans;
Immunization;
Immunization Schedule;
Korea;
Vaccination
- From:Korean Journal of Infectious Diseases
1998;30(1):69-74
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Several studies on the efficacy and safety of the hepatitis B vaccine have shown variable immunogenicity. In this study we reexamined the immunogenicity and safety of recombinant hepatitis B vaccine, Engerix B which have currently been administered to the children in Korea. METHODS: Serum samples were collected from 126 children and 111 adults who were immunized according to the 0, 1, 2-month and 0, 1, 6-month vaccination schedule. Anti-HBs antibody titers were measured by ELISA in sera obtained after each immunization, and compared by immunization schedules. RESULTS: In 62 children with 0, 1, 2-month immunization schedule seroconversion rate was 83.9% after 1st vaccination, 96.8% after 2nd, and 98.4% after 3rd. In 64 children with 0, 1, 6-month immunization schedule seroconversion rates was 78.1% after 1st vaccination, 87.5% after 2nd and 100% after 3rd. In 50 adults immunized with 0, 1, 2-month schedule seroconversionrates was 48.0% after 1st vaccination, 74.0% after 2nd and 90.0% after 3rd. In 61 adults immunized with 0, 1, 6-month schedule seroconversion rate was 44.3% after 1st vaccination, 65.6% after 2nd and 93.4% after 3rd. Seroconversion rate after 0, 1, 2- month vaccination schedule were 98.4% in children and 90.0% in adults. Seroconversion rate after 0, 1, 6-month schedule were 100% in children and 93.4% in adults. There were no significant local and systemic untoward reactions among vaccinees. CONCLUSION: The recombinant Engerix B is excellent in immunogenicity with 93.4% and 100% seroconversion rates in adults and children, respectively. There is no significant difference in seroconversion rate between two vaccination schedule. The vaccine is safe.
